Trial
NCT06317285
A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
GlaxoSmithKline
Collaborators
—
Condition
Idiopathic Pulmonary Fibrosis
Intervention
GSK3915393
Why stopped
The study met futility criteria at pre-planned interim analysis, showing no clinical efficacy of the investigational drug. Based on the lack of efficacy at the interim data review, the sponsor decided to terminate the study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-03-13